Table of Content

1. CD 47 As Novel Cancer Immunotherapy Target


2. Global CD47 Inhibitors Drug Clinical Pipeline Overview
2.1 By Country
2.2 By Company
2.3 By Indication
2.4 By Patient Segment
2.5 By Phase
2.6 By Priority Status


3. CD47 Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase
3.1 Research
3.2 Preclinical
3.3 Phase I
3.4 Phase I/II
3.5 Phase II
3.6 Phase II/III
3.7 Phase III


4. Global CD47 Inhibitor Drug Market Opportunity Outlook
4.1 Current Market Overview
4.2 Future Outlook & Opportunities


5. CD47 Clinical Application & Development Outlook by Indication

5.1 Solid Cancers
5.1.1 Breast Cancer
5.1.2 Colorectal Cancer
5.1.3 Lung Cancer
5.1.4 Urogenital Cancer
5.1.5 Gastrointestinal Cancer

5.2 Hematological Malignancies
5.2.1 Lymphoma

5.2.2 Leukemia
5.2.3 Multiple Myeloma
5.2.4 Myelodysplastic Syndrome

5.3 Microbial Infections


6. CD47 Inhibitor Drugs Clinical Developments & Trends By Country
6.1 China
6.2 US
6.3 South Korea
6.4 Australia
6.5 Canada


7. Global CD47 Inhibitors Market Dynamics
7.1 Favorable Parameters
7.2 Market Restraints


8. Competitive Landscape
8.1 Adagene
8.2 ALX Oncology
8.3 ImmuneOncia Therapeutics
8.4 ImmuneOnco Biopharma
8.5 Light Chain Bioscience
8.6 Phanes Therapeutics
8.7 Virtuoso Therapeutics
 



List of Figures

Figure 2-1: Global – Number of CD47 Inhibitor Drugs Clinical Trial By Country, 2022 Till 2028
Figure 2-2: Global – Number of CD47 Inhibitor Drugs In Clinical Pipeline By Company, 2022 Till 2028
Figure 2-3: Global – Number of CD47 Inhibitor Drugs In Clinical Pipeline By Indication, 2022 Till 2028
Figure 2-4: Global – Number of CD47 Inhibitor Drugs In Clinical Pipeline By Patient Segment, 2022 Till 2028
Figure 2-5: Global – Number of CD47 Inhibitor Drugs In Clinical Pipeline By Phase, 2022 Till 2028
Figure 2-6: Global – Number of CD47 Inhibitor Drugs In Clinical Pipeline By Priority Status, 2022 Till 2028

Figure 5-1: NI-1801 Phase I Study (NCT05403554) – Initiation & Completion Year
Figure 5-2: ALX148 Phase I Study (NCT05868226) – Initiation & Completion Year
Figure 5-3: Ligufalimab Phase II Study (NCT05382442) – Initiation & Completion Year
Figure 5-4: PT217 Phase I/II Study (NCT05652686) – Initiation & Completion Year
Figure 5-5: HMPL-A83 Phase I Study (NCT05429008) – Initiation & Completion Year
Figure 5-6: ALX148 Phase I Study (NCT05524545) – Initiation & Completion Year
Figure 5-7: PT217 Phase I/II Study (NCT05652686) – Initiation & Completion Year
Figure 5-8: AK117 Phase II Study (NCT05382442) – Initiation & Completion Year
Figure 5-9: AK117 Phase I/II Study (NCT05214482) – Initiation & Completion Year
Figure 5-10: AK117 Phase II Study (NCT05960955) – Initiation & Completion Year
Figure 5-11: Evorpacept Phase II/III Study (NCT05002127) – Initiation & Completion Year
Figure 5-12: PT886 Phase I/II Study (NCT05482893) – Initiation & Completion Year
Figure 5-13: CC-96673 Phase I Study (NCT04860466) – Initiation & Completion Year
Figure 5-14: HCB101 Phase I Study (NCT05892718) – Initiation & Completion Year
Figure 5-15: Evorpacept Phase I/II Study (NCT05025800) – Initiation & Completion Year
Figure 5-16: AK117 Phase I/II Study (NCT04980885) – Initiation & Completion Year
Figure 5-17: AK117 Phase I/II Study (NCT06387420) – Initiation & Completion Year
Figure 5-18: TQB 2928 Phase I Study (NCT06008405) – Initiation & Completion Year

Figure 5-19: SL-172154 Phase I Study (NCT05275439) – Initiation & Completion Year
Figure 5-20: SL-172154 Phase Ib Study (NCT05275439) – Initiation & Completion Year
Figure 5-21: Ligufalimab Phase Ib Study (NCT04900350) – Initiation & Completion Year

Figure 6-1: South Korea - Prominent CD47 Inhibitor Developers

Figure 7-1: Global CD47 Inhibitors Market - Drivers & Opportunities
Figure 7-2: Global CD47 Inhibitors Market - Challenges & Restraints

List of Tables

Table 5-1: Breast Cancer – Some CD47 inhibitors In Clinical Trials
Table 5-2: Colorectal Cancer – Some CD47 inhibitors In Clinical Trials
Table 5-3: Lung Cancer – Some CD47 inhibitors In Clinical Trials
Table 5-4: Urogenital Cancer – Some CD47 inhibitors In Clinical Trials
Table 5-5: Gastrointestinal Cancer – Some CD47 inhibitors In Clinical Trials
Table 5-6: Lymphoma – Some CD47 inhibitors In Clinical Trials
Table 5-7: Leukemia – Some CD47 inhibitors In Clinical Trials
Table 5-8: Colorectal Cancer – Some CD47 inhibitors In Clinical Trials
Table 5-9: Myelodysplastic Syndrome – Some CD47 inhibitors In Clinical Trials